Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

87.03 -0.97 (-1.10%)
Official Closing Price Updated: 4:10 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,343,907
Open 88.11
Bid (Size) 87.00 (1)
Ask (Size) 87.10 (3)
Prev. Close 88.00
Today's Range 86.93 - 88.11
52wk Range 73.31 - 105.11
Shares Outstanding 2,531,374,696
Dividend Yield 3.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking At Merck & Co's Recent Unusual Options Activity
 
Via Benzinga
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga

Performance

YTD
-12.2%
-12.2%
1 Month
+10.8%
+10.8%
3 Month
+3.5%
+3.5%
6 Month
+4.6%
+4.6%
1 Year
-16.5%
-16.5%

More News

Read More
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity
Via Benzinga
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Dividend-Paying Drug Stocks to Buy at a Discount
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Merck & Co Inc?
Via Benzinga
3 Healthcare Stocks to Buy Hand Over Fist in October
Via The Motley Fool
Topics Intellectual Property
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
From Merck & Co., Inc.
Via Business Wire
3 Healthcare Stocks That Are Screaming Deals Right Now
Via The Motley Fool
Topics Intellectual Property
Flash PMI: The Early Warning System Guiding the Federal Reserve's Hand
Via MarketMinute
Topics Bonds Economy Supply Chain
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop
Via The Motley Fool
Topics Energy Regulatory Compliance
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally
Via The Motley Fool
Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
From Merck & Co.
Via Business Wire
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
From Merck & Co., Inc.
Via Business Wire
What's Going On With Summit Therapeutics Stock On Monday?
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
From Merck & Co., Inc.
Via Business Wire
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 87.03
When was Merck & Co last traded?
The last trade of Merck & Co was at 10/28/25 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 220.31B
How many shares of Merck & Co are outstanding?
Merck & Co has 220B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.